Ahmedabad: Zydus Lifesciences Limited has announced that it has entered into a definitive agreement with Agenus Inc. to ...

National Pharmaceutical Pricing Authority notifies retail prices of 41 new drugs: Gireesh Babu, New Delhi Thursday, June 5, 2025, 08:00 Hrs [IST] The National Pharmaceutical Prici ...

Agenus will give Zydus an exclusive licence for the development and commercialisation of BOT and BAL in Sri Lanka and India.

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in the US market. Despite the positive numbers, Citi has maintained its 'sell' ...

Q4 results today: On Tuesday, May 20, 2025, at least 142 companies, including Religare Enterprises, NHPC and Zydus Lifesciences, are scheduled to announce financial results for the quarter ended ...

Market Share - Sugar Free: 95.9% in the sugar substitute category. Zydus Wellness Ltd (BOM:531335) reported a consolidated net sales growth of 17% for the quarter, with a volume growth of 13% year ...

Zydus Wellness Ltd on Monday reported a 14.4 per cent rise in consolidated net profit at Rs 171.9 crore in the fourth quarter ended March 31, 2025, driven by strong performance of its food and ...

Zydus Wellness Ltd. on Monday announced that it has received board nod to split its existing equity shares into five. The company has also announced a final dividend of Rs 6 per share. One equity ...

The combination of repaglinide and metformin provides comprehensive glycemic control, as well as a stable weight profile and fewer hypoglycemic episodes. The single-tablet combination of ...